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AMSTAR 2: a critical appraisal tool for systematic
reviews that include randomised or non-randomised
studies of healthcare interventions, or both
The number of published systematic reviews of studies of healthcare interventions has increased
rapidly and these are used extensively for clinical and policy decisions. Systematic reviews are
subject to a range of biases and increasingly include non-randomised studies of interventions. It is
important that users can distinguish high quality reviews. Many instruments have been designed to
evaluate different aspects of reviews, but there are few comprehensive critical appraisal instruments.
AMSTAR was developed to evaluate systematic reviews of randomised trials. In this paper, we
report on the updating of AMSTAR and its adaptation to enable more detailed assessment of
systematic reviews that include randomised or non-randomised studies of healthcare interventions,
or both. With moves to base more decisions on real world observational evidence we believe that
AMSTAR 2 will assist decision makers in the identification of high quality systematic reviews,
including those based on non-randomised studies of healthcare interventions.
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With the rapid increase in biomedical publishing, keeping up
with primary research has become almost impossible for
healthcare practitioners and policy makers.1 Consequently,
healthcare decision makers rely on systematic reviews as one
of the key tools for achieving evidence based healthcare.2
Systematic reviews provide an opportunity to base decisions
on accurate, succinct, credible, and comprehensive summaries
of the best available evidence on a topic.2
Uncritically accepting the results of a single systematic review
has risks. One of us (DM) led efforts to improve standards for
reporting of systematic reviews, which led to the PRISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses) statement.3 The reporting guide for systematic
reviews of observational (non-randomised) studies is MOOSE
(Meta-analysis of Observational Studies in Epidemiology).4 The
quality of reporting of a systematic review may, however, more
accurately reflect authors’ ability to write in a comprehensible
manner rather than the way they conducted their review. This
underscores the need for guidelines that evaluate the way in
which reviews are planned and conducted.5 6
The Cochrane Collaboration Handbook provides a
comprehensive guide for review authors, but it does not provide
a concise critical appraisal instrument for completed reviews.5
Several instruments have been designed to evaluate individual
studies that are being included in systematic reviews or how
certain steps (eg, meta-analysis, testing for publication bias)
Correspondence to: B J Shea bevshea@uottawa.ca
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2017;358:j4008 doi: 10.1136/bmj.j4008 (Published 2017 September 21) Page 1 of 8
Research Methods & Reporting
RESEARCH METHODS & REPORTING
Summary points
Systematic reviews of studies of healthcare interventions effects often include non-randomised studies
AMSTAR is a popular instrument for critically appraising systematic reviews of randomised controlled clinical trials
AMSTAR underwent further development to enable appraisal of systematic reviews of randomised and non-randomised studies of
healthcare interventions
The revised instrument (AMSTAR 2) retains 10 of the original domains, has 16 items in total (compared with 11 in the original), has
simpler response categories than the original AMSTAR, includes a more comprehensive user guide, and has an overall rating based
on weaknesses in critical domains
AMSTAR 2 is not intended to generate an overall score
With moves to base more decisions on real world observational evidence, AMSTAR 2 should assist in the identification of high quality
systematic reviews
should be conducted.7-15 But relatively few instruments assess
all important steps in the conduct of a review.16-21
AMSTAR (A MeaSurement Tool to Assess systematic
Reviews), published in 2007, is one of the most widely used
instruments.22-24 AMSTAR was designed by us and our
colleagues as a practical critical appraisal tool for use by health
professionals and policy makers who do not necessarily have
advanced training in epidemiology, to enable them to carry out
rapid and reproducible assessments of the quality of conduct of
systematic reviews of randomised controlled trials of
interventions. Since publication, several critiques of the
instrument have been published.25-31 These critiques plus
feedback received at workshops and developments in the science
of systematic reviews pointed to a need to revise and update the
original AMSTAR instrument.
Inclusion of non-randomised studies in
systematic reviews
Almost half of published systematic reviews now include
non-randomised studies of intervention effects.4-34 There are
many concerns about the conduct and reporting of systematic
reviews of non-randomised studies.32-36 To summarise,
non-randomised studies of healthcare interventions (an important
focus of this revision of AMSTAR) are subject to a range of
biases that are either not present or are less noticeable in
randomised controlled trials, thus requiring different risk of bias
assessments. Observational studies are increasingly conducted
within large population databases, sometimes with hundreds of
thousands or even millions of recipients of healthcare
interventions. These generate precise estimates of intervention
effects, which may be inaccurate because of residual biases. If
these estimates are combined with those from the (generally
smaller) randomised controlled trials, the meta-estimates will
be weighted towards the observational study estimates. The
original AMSTAR instrument did not include an assessment of
the risk of bias in non-randomised studies included in a review,
which is a key issue given the diversity of designs that such
studies may use and the biases that may affect them.
Development of AMSTAR 2
The development and validation of the original AMSTAR
instrument (published in 2007) has been described in detail
elsewhere.22-24 Briefly, the original list of items was created from
the results of a scoping review of the then available rating
instruments. This review identified many over-lapping appraisal
items, mainly from two extensively cited reports.16 17 The lists
of items from these reports were combined and reduced by factor
analysis. After pilot testing, items were reworded as needed and
the reliability and usability of the tool was assessed. A modified
version was validated externally and performed well against the
global judgments of a panel of content experts.23 The
publications describing the original AMSTAR instrument were
widely cited and the instrument has been used and critiqued
extensively.22-31
We convened an expert group, comprising authors of the original
instrument, members with expertise in the conduct of
non-randomised studies, development of appraisal instruments,
biostatistics, and study designs. The expert group met for a day
in Ottawa, Canada and members were presented with the results
of updated literature reviews on relevant critical appraisal
instruments, the results of surveys of AMSTAR users, recorded
experience of participants in AMSTAR workshops at Cochrane
Colloquiums in 2015 and 2016, feedback from the AMSTAR
website (www.amstar.ca), and published critiques of the original
instrument.16-26 The perspective adopted by the expert group was
to increase the value of AMSTAR as a broad critical appraisal
instrument designed primarily for systematic reviews of studies
of healthcare interventions. The expert group considered that
revisions should address all aspects of the conduct of a
systematic review, and the challenges of including
non-randomised studies. They also thought the revised
instrument should function as a teaching aid and as a concise
checklist for those conducting reviews. The revisions were not
intended to deal with the special requirements of diagnostic test
reviews, individual patient data meta-analyses or network
meta-analyses, scoping reviews, or realist reviews.37-41
We used a nominal group technique to propose and then
prioritise specific changes to the instrument and to agree on the
draft wording of items. Based on their experience of the
instrument and the presentations made at the meeting,
participants were asked to record their ideas independently and
privately. The ideas were then enunciated in a round-robin
format. One idea was collected from everyone, in turn, and
presented to the group by the facilitator. This process was
continued until all ideas had been listed. Individuals then
privately recorded their judgments and rankings. These were
aggregated statistically to derive the group judgments. The
following changes were agreed on (these are not listed in order
of priority as all were considered important enough to mandate
modifications to the instrument):
•Simplify the response categories
•Align the definition of research questions with the PICO
(population, intervention, control group, outcome)
framework
•Seek justification for the review authors’ selection of
different study designs (randomised and non-randomised)
for inclusion in systematic reviews
•Seek more details on reasons for exclusion of studies from
the review
•Determine whether the review authors had made a
sufficiently detailed assessment of risk of bias for the
included studies (whether randomised or non-randomised)
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•Determine whether risk of bias with included studies was
considered adequately during statistical pooling of results
(if this was performed)
•Determine whether risk of bias with included studies was
considered adequately when interpreting and discussing
the review findings.
A description was formulated for each of the draft items. A
small subgroup refined the wording of the items and assembled
the draft instrument for testing. Initial pilot testing was
performed by group members. Draft versions were presented
at workshops held at the Cochrane Colloquiums in 2015 and
2016, where feedback directed further modifications and
redrafting of the instrument. The version of the instrument
presented here was subject to inter-rater reliability and usability
testing.
Comparison with the original instrument
The supplementary figure provides details of the new instrument
(AMSTAR 2). Ten domains were retained from the original
tool, with changes to the wording of items based on feedback
about the original instrument and experience of testing drafts
of the new instrument. Two domains were given more detailed
coverage in AMSTAR 2 than in the original instrument:
duplicate study selection and data extraction now have their
own items (they were combined in the original tool). The
possible influence of funding sources is now considered
separately for individual studies included in the review and for
the review itself. Previously they were combined in one item.
We added more detailed and separate considerations of risk of
bias for randomised and non-randomised studies. Both sub-items
are based on content from the Cochrane risk of bias instruments
for randomised and non-randomised (ROBINS-I) studies.42 43
One domain was removed—consideration of grey literature,
previously a separate item, is now handled in the item on
literature searching.
In total, four domains were added. Two of these came directly
from the ROBINS-I tool—namely, elaboration of the PICO and
the way in which risk of bias was handled during evidence
synthesis.43 One of the other new domains—discussion of
possible causes and significance of heterogeneity—is an
elaboration of content in the original AMSTAR tool. Another
new domain—justification of selection of study designs—was
part of the adaptation of AMSTAR to deal with non-randomised
designs.
The domain specific questions in AMSTAR 2 are framed so
that a “Yes” answer denotes a positive result. We removed the
“not applicable” and “cannot answer” options in the original
AMSTAR instrument because we believe that all domains are
relevant to contemporary systematic reviews of healthcare
interventions. If no information is provided to rate an item, the
review authors should not be given the benefit of doubt and the
item should be rated as a “No.” We have provided a “partial
Yes” response in some instances where we considered it
worthwhile to identify partial adherence to the standard.
Rationale for selection of items
Here we summarise our thinking behind the items in AMSTAR
2, which are numbered as in the instrument (see supplementary
figure). Supplementary appendix 1 provides a more complete
user’s guide.
1. Did the research questions and inclusion criteria for the
review include the components of PICO?
It is common practice to use the PICO description (population,
intervention, control group, and outcome) as a convenient and
easily memorised framework for a study question. Sometimes
a timeframe should be added if this is critical in determining
the likelihood of a study capturing relevant clinical outcomes
(eg, an effect of the intervention is only expected after several
years).
2. Did the report of the review contain an explicit statement
that the review methods were established prior to the conduct
of the review and did the report justify any significantdeviations
from the protocol?
Systematic reviews are a form of observational research, and
the methods for the review should be agreed on before the
review commences. Adherence to a well developed protocol
reduces the risk of bias in the review. Authors should show that
they worked with a written protocol with independent
verification.
3. Did the review authors explain their selection of the study
designs for inclusion in the review?
For some questions, for instance the effects of policy changes,
or for ethical reasons, non-randomised studies may be the only
studies addressing the review question. With an expansion of
AMSTAR 2 to appraise reviews that include randomised
controlled trials or non-randomised studies, or both, it is
important that authors justify the inclusion of different study
designs in systematic reviews. The authors should indicate that
they followed a strategy. When both randomised and
non-randomised studies address the same question about the
effects of an intervention, we believe that authors should
consider whether a review that is restricted to randomised
controlled trials will give an incomplete summary of the
important effects of a treatment.
4. Did the review authors use a comprehensive literature search
strategy?
The importance of adequate literature searching in systematic
reviews is well established.5 This item was carried over with
minimal changes to the wording from the original instrument.
We have made the response options clearer in AMSTAR 2 and
provide more detailed guidance on completion of the item,
particularly in relation to the identification of non-randomised
studies (see supplementary appendix 1).
5. Did the review authors perform study selection in duplicate?
Best practice requires two review authors to determine eligibility
of studies for inclusion in systematic reviews.5 This involves
checking the characteristics of a study against the elements of
the research question. In the original AMSTAR, this item
covered determining both study eligibility and data extraction.
The expert group believed that they were sufficiently distinct
processes to merit separate items in AMSTAR 2.
6. Did the review authors perform data extraction in duplicate?
The expert group recognised that data extraction might be more
complex for non-randomised studies of healthcare interventions
as it usually involves extraction of measures of treatment effects
and other associations that have been adjusted for potential
confounding, rather than raw outcome data from treated and
control groups. A study report may present multiple treatment
effects; judgment is therefore needed to select the one that
conforms best to the PICO question and is at lowest risk from
confounding.
7. Did the review authors provide a list of excluded studies and
justify the exclusions?
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In the revised instrument we consider excluded and included
studies separately. Excluded studies should be accounted for
fully by review authors, otherwise there is a risk that they remain
invisible and the impact of their exclusion from the review is
unknown.
8. Did the review authors describe the included studies in
adequate detail?
The revised instrument requires review authors to provide detail
about research designs, study populations, interventions,
comparators, and outcomes. The detail should be sufficient for
appraisers to make a judgment about the extent to which the
studies were appropriately chosen (in relation to the PICO) and
whether the study populations and interventions were relevant
to their questions. This information is needed to determine the
extent to which the results of different studies should be
combined, help explain heterogeneity, and assist those applying
the results.
9. Did the review authors use a satisfactory technique for
assessing the risk of bias (RoB) in individual studies that were
included in the review?
Biases can be introduced at several stages in the design,
planning, conduct, and analysis of a study. This item replaces
a less detailed item on “scientific quality.” The item specifies
domains of bias for randomised and non-randomised studies
that should have been considered by reviewers, based on the
relevant Cochrane instruments.42 43 In AMSTAR 2 we ask
whether the review authors made an adequate assessment of
study level efforts to avoid, control, or adjust for baseline
confounding, selection biases, bias in measurement of exposures
and outcomes, and selective reporting of analyses or outcomes,
or both. The guidance document (see supplementary appendix
1) and the ROBINS-I report provide more detail.43 We decided
not to include assessment of time varying confounding,
performance biases, and biases due to missing data, although
they are currently included in ROBINS-I.43 This was because
of the complex nature of techniques used to adjust for these
potential sources of bias and the frequent lack of data (in
contemporary primary studies) to enable assessment of these
items. Version 2.0 of the Cochrane risk of bias instrument for
randomised controlled trials is now available in draft form, and
AMSTAR 2 will be aligned with this in the future.44
10. Did the review authors report on the sources of funding for
the studies included in the review?
We added a consideration of funding sources in the light of
evidence from several sources that the results of industry funded
studies sometimes favoured sponsored products, and that
industry funded studies were less likely to be published than
those that were independently funded.45-47 Such influences may
not be detected as flaws in design or methods (item 9).
11. If meta-analysis was performed, did the review authors use
appropriate methods for statistical combination of results?
This is a modified version of an item in the original instrument
and is judged separately for randomised and non-randomised
studies. Review authors should have stated explicitly in the
review protocol the principles on which they based their decision
to perform meta-analysis of data from the included studies. This
includes the extent to which the studies are compatible (in terms
of patients, controls, and interventions) and the value of a single
pooled effect (for instance from several compatible but
underpowered studies). Where reviewers consider it appropriate
to conduct a meta-analysis, the inclusion of non-randomised
studies increases the complexity of the analyses and may
increase heterogeneity (see supplementary appendix 1).
12. If meta-analysis was performed, did the review authors
assess the potential impact of RoB in individual studies on the
results of the meta-analysis or other evidence synthesis?
This is a new item that requires reviewers to examine how
results vary with inclusion or exclusion of primary studies
judged to be at high risk of bias. In cases where review authors
have chosen to include only high quality randomised controlled
trials there may be little discussion of the potential impact of
bias on the results. But where they have included randomised
controlled trials of variable quality or non-randomised studies
they should assess the impact of study level risk of bias on the
results of the review.48
13. Did the review authors account for RoB in primary studies
when interpreting/discussing the results of the review?
This is a modification of an item from the original instrument.
With a greater emphasis on assessing risk of bias, the
expectation is that reviewers will make explicit reference to the
potential impacts of risk of bias when interpreting and discussing
the results of their review and in drawing conclusions or making
recommendations.
14. Did the review authors provide a satisfactory explanation
for, and discussion of, any heterogeneity observed in the results
of the review?
This item is carried over with modified wording from the
original instrument. It is important that reviewers investigate
possible causes of heterogeneity, including variation in those
elements included in the PICO framework (see item 1) and those
arising from design and methodological considerations (see
item 9). With the inclusion of non-randomised studies, variations
in design and analysis may contribute to heterogeneity.
15. If they performed quantitative synthesis did the review
authors carry out an adequate investigation of publication bias
(small study bias) and discuss its likely impact on the results of
the review?
This item is carried over from the original instrument but with
modified wording. Publication bias is an important problem but
it can be difficult for authors to resolve completely. Typically,
statistical tests (several are available) or graphical displays are
used and if the results are positive they indicate the presence of
publication bias. Negative test results are not a guarantee of the
absence of publication bias as they are insensitive. A minimum
of 10 studies are required to show funnel plot asymmetry.5 The
underlying tendency to selectively publish small positive studies
may be compounded by the effects of lower methodological
quality of small studies, a greater tendency to selectively report
results, and increased clinical heterogeneity when conducted in
patient subgroups.49
16. Did the review authors report any potential sources of
conflict of interest, including any funding they received for
conducting the review?
This item is carried over with modified wording from the
original instrument and is now separate from consideration of
funding of the primary studies included in the review (item 10).
As with primary studies, review authors should report their
funding sources.50 51
Identification of critical domains
All steps in the conduct of a systematic review and meta-analysis
are important, but we believe that seven domains can critically
affect the validity of a review and its conclusions (box 1). Two
of these concern risk of bias, whether it has been assessed
adequately and how it can influence the results of a review. The
prominence we give to risk of bias is because AMSTAR 2 is
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going to be used to appraise many systematic reviews that
include non-randomised studies.
We recognise that the items listed in box 1 will not always be
regarded as critical; for example, risk of bias related items may
be considered less important when a review is confined to high
quality randomised controlled trials. Other circumstances where
the critical nature of items may be questioned are when a review
team are using meta-analysis to summarise a known literature
base (eg, the output from one or more established clinical trial
collaborative groups). In this circumstance the adequacy of the
literature search (item 4), listing of excluded studies (item 7),
and possibility of publication bias (item 15) may not be
considered critical. If a meta-analysis was not performed, the
item covering the appropriateness of the meta-analytical methods
(item 11) will not apply. However, it is important in this
circumstance that appraisers are alert to the possible impact of
risk of bias when review authors select individual studies to
highlight in a narrative summary.
Flaws in the items that we have identified as critical may not
be fatal if further information (eg, directly from the review
authors) indicates that the original response option was wrong.
This may provide reassurance about the review findings or
enable an amendment of the review through additional analyses.
We emphasise that our listing is a suggestion and appraisers
may add or substitute other critical domains. For example, the
failure to include non-randomised studies (item 3) in a review
of adverse outcomes of treatment may be a critical flaw, as
would the inability to explain large variations in treatment
effects across a body of studies (item 14).
Applying AMSTAR 2 to systematic reviews
If one or more systematic reviews will be the basis of important
practice and policy decisions we recommend that the appraisal
team agree on how the AMSTAR 2 items should be applied.
This includes the practice or policy context and the questions
that should be addressed, based on the relevant PICO
components. For example, available systematic reviews may
have included studies with different comparators or different
follow-up times, and their relevance to the policy relevant
questions needs to be established. The likely sources of bias
should also be agreed on. For instance, in observational studies
of intervention effects, confounding by indication (or disease
severity) may be problematic when interventions are reserved
for certain subgroups of patients.52 It is good practice to recruit
new users of a technology or drug into studies to avoid
prevalence bias.53 If the start of one intervention tends to be
delayed the choice of comparator may introduce immortal time
bias.54 Measurement errors can misclassify exposure and
outcomes and may be unbalanced across comparison groups.
Selective reporting among multiple analyses and outcomes may
give an inaccurate measure of intervention effects.
Supplementary appendix 1 provides guidance on sections of
AMSTAR 2. Some of the judgments (particularly whether
review authors have adequately assessed risk of bias with
individual non-randomised studies) are complex, and advice on
both methodology and content may be needed. Content
knowledge is sometimes necessary to determine if the review
authors have made an adequate assessment of the relevant PICO
elements (item 1), and to identify potential confounders.
We strongly recommend that individual item ratings are not
combined to create an overall score.55 56 Rather, users should
consider the potential impact of an inadequate rating for each
item.
In box 2 we propose a scheme for interpreting weaknesses
detected in critical and non-critical items. This is advisory and
appraisers should decide which items are most important for
the reviews under consideration.
Inter-rater reliability of AMSTAR 2
We measured inter-rater agreement with three pairs of raters
and three sets of systematic reviews (see supplementary
appendix 2). The first pair of raters was involved in the
development of AMSTAR 2 (coauthors MT and CH). They
individually appraised 20 systematic reviews derived from a
rapid search (conducted in 2015 on the terms “systematic
review” and “meta-analysis” in the title) using Google Scholar.
From the first 200 we selected 20 systematic reviews of any
healthcare intervention. The other two pairs of raters were
experienced in the appraisal of systematic reviews and were not
involved in the development of AMSTAR or AMSTAR 2. They
applied AMSTAR 2 during their routine work, performing
appraisals of systematic reviews of two topics: interventions to
reduce medication errors (14 reviews) and non-pharmacological
therapies for Parkinson’s disease (20 reviews) (see references
in supplementary appendix 2). In both cases systematic reviews
had been identified through comprehensive literature searches
(details available on request). All raters had access to the user
guide (see supplementary appendix 1), applied the instrument
individually, and did not try to achieve consensus. In total, six
raters applied the instrument to 54 systematic reviews, of which
20 included only randomised controlled trials, 18 included only
non-randomised studies of interventions, and 16 included a
mixture of both designs.
Supplementary appendix 2 provides summaries of the κ scores
for agreement between the three pairs of raters across the three
sets of reviews. The values varied substantially across items
and between pairs of raters. Most values were in an acceptable
range, with 46 of the 50 κ scores falling in the range of moderate
or better agreement and 39 displaying good or better agreement.
There were no large differences between raters, and those who
had been involved in the development of AMSTAR 2 did not
have higher levels of agreement than the rater who was not
involved. Items 9, 12, and 13 are concerned with measurement
of risk of bias and how this is handled during discussion of the
meta-analysis and interpretation of the results. The ranges of κ
scores for these items were similar to those seen with other
items in the instrument (see supplementary appendix 2). For
items 9 and 11 the κ values for risk of bias judgments for
randomised controlled trials were similar to those for
non-randomised studies.
Usability of AMSTAR 2
The completion times for the 20 reviews used by reviewers 1
and 2 ranged from 15-32 minutes. These estimates do not
include the time taken to read the reviews. This is almost twice
the time taken to complete the original AMSTAR instrument
(range 10-15 minutes), when it was applied to systematic
reviews that were limited to randomised controlled trials.57 The
comments from the reviewers included: that the removal of the
“can’t answer” and “not applicable” response options in the
original instrument forced them to make judgments; that it takes
longer to evaluate the non-randomised and mixed study reviews,
but this requires the reviewer to confront important
methodological issues; that it was common for review authors
to mention the presence or absence of publication bias, but not
provide any evidence; and that review authors would disclose
their potential competing interests but not how they managed
them.
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Box 1 AMSTAR 2 critical domains
• Protocol registered before commencement of the review (item 2)
• Adequacy of the literature search (item 4)
• Justification for excluding individual studies (item 7)
• Risk of bias from individual studies being included in the review (item 9)
• Appropriateness of meta-analytical methods (item 11)
• Consideration of risk of bias when interpreting the results of the review (item 13)
• Assessment of presence and likely impact of publication bias (item 15)
Box 2 Rating overall confidence in the results of the review
High
No or one non-critical weakness: the systematic review provides an accurate and comprehensive summary of the results of the available
studies that address the question of interest
Moderate
More than one non-critical weakness*: the systematic review has more than one weakness but no critical flaws. It may provide an
accurate summary of the results of the available studies that were included in the review
Low
One critical flaw with or without non-critical weaknesses: the review has a critical flaw and may not provide an accurate and comprehensive
summary of the available studies that address the question of interest
Critically low
More than one critical flaw with or without non-critical weaknesses: the review has more than one critical flaw and should not be relied
on to provide an accurate and comprehensive summary of the available studies
*Multiple non-critical weaknesses may diminish confidence in the review and it may be appropriate to move the overall
appraisal down from moderate to low confidence
Discussion
AMSTAR 2 is a major revision of the original AMSTAR
instrument, which was designed to appraise systematic reviews
that included randomised controlled trials.22-24 The main
modifications include simplified response categories; a more
detailed consideration of risk of bias with included studies, and
how this was handled by review authors in summarising and
interpreting the results of their reviews; better alignment with
the PICO framework for research questions; a more detailed
justification of selection of study designs for inclusion in a
review; and more information on studies that were excluded
from reviews. In addition, we recommend defining critical
domains before starting an appraisal of a systematic review.
Identification of weaknesses in these domains should undermine
confidence in the results of a systematic review.
We stress that responses to AMSTAR 2 items should not be
used to derive an overall score.55 56 The original AMSTAR
instrument was often used for this purpose and this was
facilitated by the website (www.amstar.ca). We accept that an
overall score may disguise critical weaknesses that should
diminish confidence in the results of a systematic review and
we recommend that users adopt the rating process based on
identification of critical domains (see box 2), or some variation
based on these principles.56
We envisage that AMTAR 2, like its predecessor, may have a
role as a convenient teaching aid and as a brief checklist for
those conducting systematic reviews. However, we stress that
the instrument does not explain in detail the logic and methods
of conducting systematic reviews, and those looking for
comprehensive advice should consult the Cochrane Handbook.5
The consideration of risk of bias in individual studies is equally
important for randomised and non-randomised studies of
healthcare interventions but is generally better understood with
the former. Large non-randomised studies, often conducted in
large administrative databases, are increasingly being used to
assess the real world impact of a wide range of healthcare
technologies and practices. Although such studies often use
sophisticated methods, residual confounding or failure to deal
with other sources of bias may lead to inaccurate estimates of
effect. Inclusion of large observational studies in meta-analyses
may generate precise but biased estimates of intervention
effects.32
The items in AMSTAR 2 that deal with risk of bias identify
domains specified in the Cochrane risk of bias instruments for
randomised and non-randomised studies.42 43 These represent a
consensus, in each case developed with input from more than
30 experts in methodology. However, AMSTAR 2 does not
currently specify which risk of bias instruments review authors
should have used to assess non-randomised studies included in
a systematic review. The ROBINS-I instrument, which is the
most comprehensive tool for non-randomised studies evaluating
the effects of healthcare interventions, was released in 2016 and
it is unrealistic to expect authors of reviews started before its
release to have used it.43 Presently, AMSTAR 2 leaves it to the
review authors and those appraising the review to satisfy
themselves that the risk of bias instrument used by review
authors has sufficient discriminatory ability for the specified
risk of bias domains. A review by Sanderson and colleagues
identified 86 tools for assessing quality of observational studies,
without a clear preference among them.58 The authors pointed
to the need to agree on critical elements for assessing
susceptibility to bias in observational epidemiology. In part this
review led to the development of ROBINS-I.43 Popular appraisal
instruments for individual studies, such as the Newcastle Ottawa
Scale and the Scottish Intercollegiate Guidelines Network
(SIGN) checklist may not focus on validity alone.59 60 The
Newcastle Ottawa Scale appears to lack sensitivity and is
sometimes used to generate an overall score, something that is
not recommended because it may disguise critical weaknesses
in a review.56 61
AMSTAR 2, as a critical appraisal instrument for systematic
reviews, joins several published instruments designed for this
purpose.3-62 Two prominent examples are concerned with
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guidelines for reporting systematic reviews, rather than their
conduct.3 4 Two highly cited instruments were the basis for the
development of the original AMSTAR tool.16-22 Two published
instruments are direct derivatives of the original AMSTAR.19 25
Another publication includes a checklist used to appraise
systematic reviews that are being included in an umbrella
review.20 Overlap between the content of this checklist and the
original AMSTAR is considerable.22
AMSTAR 2 provides a broad assessment of quality, including
flaws that may have arisen through poor conduct of the review
(with uncertain impact on findings). In this respect it differs
from another instrument, the Risk Of Bias In Systematic reviews
(ROBIS).62 ROBIS is a sophisticated three phase instrument
that focuses specifically on the risk of bias introduced by the
conduct of the review. It covers most types of research question,
including diagnosis, prognosis, and aetiology. In contrast,
AMSTAR 2 is intended to be used for reviews of healthcare
interventions. Inevitably there is overlap in the items considered
by ROBIS and AMSTAR 2; indeed, two investigators (BCR,
BJS) were involved in the development of both.
In developing AMSTAR 2 we sought to maintain its familiar
and popular stepwise checklist approach and augmented this by
the addition and modification of items. AMSTAR 2 will be
familiar to users of the original instrument, although more
demanding to use for reasons discussed previously. Because
AMSTAR 2 is structured around the key sequential steps in the
conduct of a systematic review, it may be used as a brief
teaching aid or as a checklist by those conducting systematic
reviews.
Unlike the original instrument, AMSTAR 2 identifies critical
weaknesses (see box 1) that should reduce confidence in the
findings of a review, and it asks users to prespecify how this
list will vary for the review topic. We understand that there will
be debate about membership of this list and propose that users
may wish to prespecify a different set of critical items for a
specific PICO research question or setting.
We did not perform an extensive validation of the revised
AMSTAR 2 tool. In its development, 10 domains were retained
from the original validated tool, albeit with some wording
changes based on feedback and extensive experience of using
it. Two domains were given more detailed coverage: duplicate
study selection and data extraction now have their own items
(they were combined in the original tool); we have added more
detailed, and separate, considerations of risk of bias for
randomised and non-randomised studies. The sub-items were
derived from widely used Cochrane instruments. One domain
was removed; consideration of grey literature, previously a
separate item, is now handled in the item on literature searching.
In total, four domains were added. Two of these come directly
from the ROBINS-I tool—namely, elaboration of PICO in the
review and the way in which risk of bias was handled during
evidence synthesis.43 One of the other new domains, discussion
of possible causes and importance of heterogeneity, is
elaboration of content in the original AMSTAR tool.22 The final
domain, justification of selection of study designs, is justified
by adapting AMSTAR to deal with non-randomised designs.
We do not think this needs validation because we believe it is
obvious that authors of systematic reviews should justify why
they have included study designs that are more susceptible to
bias.
The levels of agreement achieved by the three pairs of raters
varied across items, but they were moderate to substantial for
most items. Notably, the agreement between two raters involved
in the development of AMSTAR 2 was no higher than that
achieved by experienced raters who had not been involved its
development. We did not expect perfect agreement, and
differences between raters reflect the demanding nature of some
item level judgments and should prompt group discussion of
their causes and importance, and, if needed, consultation with
experts in subject matter and methods.
In developing AMSTAR 2 we relied heavily on the consensus
of the expert panel, but we also received extensive feedback
from users of the original instrument in the form of direct
communications, website comments, and evaluations made at
teaching workshops at Cochrane Colloquiums. In the later
phases of development of AMSTAR 2 we had access to, and
discussed, recently published critiques of AMSTAR.25-31
Our experience of releasing and using the original AMSTAR
instrument is that judgments need to be made and users may
sometimes decide to make modifications to the instrument.25-30
We encourage investigators to provide feedback, and, if they
adapt the instrument for particular settings, to report their
experience at www.amstar.ca.
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